에이프로젠바이오로직스: management transactions · South Korea · DART (FSS) DART:company-260880 KR KR · DART (FSS) Mcap 102.5Bn€
Browse the full directors' dealings record of 에이프로젠바이오로직스, a listed issuer based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Market capitalisation: €102.5bn. The latest transaction was filed on 8 May 2026 — Sale. Among the most active insiders: 에이프로젠. All data is accessible without an account.
Financial data FY ended December 2025 · cache
Income statement
Revenue 73.23 Bn€
Gross profit −27.03 Bn€ -37% margin
Net income −170.33 Bn€ -232.6% margin
Balance sheet & cash
Market cap 102.54 Bn€
Total debt 228.80 Bn€
Free Cash Flow −48.01 Bn€
Last declaration on 8 May 2026
Declarations 13 total
Executives ● Sale22 DART
DART:20260508000643 · 8 May 2026
Executives ● Sale2 DART
DART:20260508000809 · 8 May 2026
Executives ● Sale2 DART
€1m 592,592 shares
DART:20260508000762 · 8 May 2026
Executives ● Sale7 DART
DART:20260508000702 · 8 May 2026
Executives ● Sale7 DART
DART:20260508000688 · 8 May 2026
Executives ● Sale7 DART
DART:20260508000659 · 8 May 2026
Executives ● Sale7 DART
DART:20260508000674 · 8 May 2026
Executives ● Purchase2 DART
€16m 7,261,801 shares
DART:20260430001304 · 30 Apr 2026
Ideal exit: 25 Jan 2027 (T+270) Executives ● Sale2 DART
DART:20260430001347 · 30 Apr 2026
Executives ● Sale2 DART
€679m 314,783,146 shares
DART:20260416000553 · 16 Apr 2026
Executives ● Other2 DART
0
DART:20260403003348 · 3 Apr 2026
Executives ● Purchase2 DART
€8m 2,881,617 shares
DART:20260330001332 · 30 Mar 2026
Ideal exit: 25 Dec 2026 (T+270) Executives ● Purchase2 DART
€94m 35,824,292 shares
DART:20260327001300 · 27 Mar 2026
Ideal exit: 22 Dec 2026 (T+270)